
Opinion|Videos|September 16, 2024
BTK Inhibitor-Associated Adverse Events
The discussion explores the evolution of understanding adverse events (AEs) related to Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment and identifies the primary classwide AEs associated with these therapies.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- How has the understanding of adverse events associated with Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment evolved, and what are the primary classwide adverse events?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Implementing Enfortumab Vedotin-ejfv Plus Pembrolizumab: Navigating Safety Data and the Pharmacist’s Role
2
Daratumumab Boosts Depth and Durability of Response After ASCT, Offering Clear Guidance for Pharmacist Counseling
3
Improving Outcomes in Diffuse B-Cell Lymphoma Requires Multidisciplinary Evolution
4
American Cancer Society Updates Cervical Cancer Screening Guidelines to Include Self-Collection for HPV Testing
5













































































































































































































